BioGenix Revenue and Competitors
Estimated Revenue & Valuation
- BioGenix's estimated annual revenue is currently $4.2M per year.
- BioGenix's estimated revenue per employee is $155,000
Employee Data
- BioGenix has 27 Employees.
- BioGenix grew their employee count by 29% last year.
BioGenix's People
Name | Title | Email/Phone |
---|
BioGenix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is BioGenix?
BioGenix grew out of the recognition of the important potential of stem cell regenerative medicine in giving hope to patients who suffer from past injuries, chronic conditions, or degenerative disease. Out of this potential grew the demand for safe, reliable, ethically sound stem cell products -- and BioGenix was up to the task. Working directly with hospitals participating in umbilical cord tissue donation programs and partnering with a trusted, sterile FDA-compliant lab, we turned concept into reality, bringing the BioGenix stem cell product to physicians across medical specialties. Learn About Our Protocol By choosing to use only umbilical cord mesenchymal stem cells, we harness the medical advantages of growth-factor rich tissue while circumventing invasive procedures and providing a product that aligns with our ethics.
keywords:N/AN/A
Total Funding
27
Number of Employees
$4.2M
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.1M | 27 | -37% | $289.6M |
#2 | $3.4M | 27 | 0% | N/A |
#3 | $2.7M | 27 | N/A | N/A |
#4 | $2.7M | 27 | N/A | N/A |
#5 | $2.7M | 27 | N/A | N/A |